UBS initiated coverage of American Healthcare REIT (AHR) with a Buy rating and $51 price target The company is facing a decade of “robust” adjusted funds from operations growth that deserves a premium valuation, the analyst tells investors in a research note. The firm sees upside to 2026 and 2027 consensus estimates, driven by greater than expected acquisition volume pushing American Healthcare’s senior housing operating portfolio exposure higher.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- Buy Rating for American Healthcare REIT, Inc. Driven by Strong AFFO Growth and Strategic Expansion in Senior Housing
- American Healthcare REIT Announces Quarterly Distribution
- American Healthcare REIT price target raised to $48 from $45 at Morgan Stanley
- American Healthcare REIT price target raised to $47 from $42 at Scotiabank
- American Healthcare REIT price target raised to $46 from $44 at Truist